-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $66

Benzinga·08/12/2026 19:14:20
Listen to the news
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $66.